All News

Next-generation sequencing was more successful in finding patients with endometrial and colorectal cancer with dMMR disease, indicating that they were eligible for immunotherapy.

I hadn’t done aerobics in decades, but it was time to be off the cancer couch.

Recent research showed that Keytruda plus chemotherapy was superior to placebo plus chemotherapy in GI cancers, although the results were not considered statistically significant.

The year 2024 is now underway. After a busy 2023, we’re now looking back at some of the oncology headlines from the new year.

Wait for the other shoe to drop, or grab each day for all it’s worth?

Vd1-gd T cells, a rare type of immune cell, have been found to potentially predict how likely it is that certain patients with advanced skin cancer will be responsive to treatment via immunotherapy, according to recently published research.

After being diagnosed with a neuroendocrine cancer, I underwent seven phases of resiliency.

An expert stressed the importance of finding a patient support group and asking questions after being diagnosed with kidney — or any other form — of cancer.

A phase 1/2 trial evaluating seclidemstat plus Vidaza resumed patient enrollment for those with certain blood cancers and another phase 1/2 trial demonstrated improved results in patients with Ewing sarcomas.

Soon after experiencing headaches and other symptoms, I spoke up to my oncologist — and I’m glad I did.

From Shannen Doherty discussing in-vitro fertilization before breast cancer to "Chickadee" Cardwell's cancer experience to be featured on an upcoming TV series, here's what's happening in the oncology space this week.

An expert explained why chemotherapy-related amenorrhea in premenopausal women with breast cancer is “not just about having a period.”

As a comfort care companion for Moffitt Cancer Center, I sat vigil next to a dying patient with cancer with no family.

Patients with relapsed/refractory mantle cell lymphoma described by one expert as “older, sicker and more heavily pretreated” than those previously studied experienced impressive responses to treatment with CAR-T cell therapy Tecartus.

An expert discusses three crucial conversations about cancer care that patients should have with their health care providers.

Exploring holistic therapies can yield some interesting findings and benefits.

Researchers have found the CAR-T cell therapy Breyanzi (lisocabtagene maraleucel) to be a cost-effective second-line treatment for patients with relapsed and refractory diffuse large B-cell lymphoma as the drug’s cost rises.

The Food and Drug Administration approved Udenyca Onbody, an administration device for Udenyca, a biosimilar of Neulasta.

Buddha once said, “To keep the body in good health is a duty... otherwise we shall not be able to keep our mind strong and clear.”

A patient in a phase 2 trial has received the first dose of a novel cancer vaccine plus Keytruda for solid skin cancer tumors.

The first patients has been dosed within the new CLARIFY trial for patients with prostate cancer awaiting prostatectomy.

The moment when I was told that my immune deficiency and rare cancer were linked.

A recent study found that breast cancer–specific survival in patients with invasive lobular carcinoma was inferior compared to patients with invasive ductal carcinoma.

The Food and Drug Administration stopped enrollment on a clinical trial evaluating LN-145 TIL for non-small cell lung cancer after a patient on the trial died.

From Jimmy Buffett's death to the chemo shortage and cannabis use in cancer care, here is a look back at some of our most popular oncology stories from 2023.

The phase 2a MYLOX-1 trial demonstrated fibrosis reduction in some patients with myelofibrosis who previously received treatment with Jakafi (ruxolitinib).

I never thought I’d say it, but I miss my padded bras.

The top stories on chronic lymphocytic leukemia from 2023 included topics like BTK inhibitors, minimal residual disease status and approaches to care for various stages of the disease.